Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Dactolisib
Cat. No.:
OB0225LY-0431
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR and HPLC.
Size:
Product Overview
Description:
Dactolisib is an oral PI3K/mTOR inhibitor with multiple-action antitumor properties.
Synonym:
BEZ235; NVP-BEZ235; 915019-65-7; 2-Methyl-2-(4-(3-methyl-2-oxo-8-(quinolin-3-yl)-2,3-dihydro-1H-imidazo[4,5-c]quinolin-1-yl)phenyl)propanenitrile; 2-Methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-ylimidazo[4,5-c]quinolin-1-yl)phenyl]propanenitrile; 2-Methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile
CAS No.:
915019-65-7
Compound CID:
11977753
Formula:
C30H23N5O
Formula Weight:
469.54
Specification
Relative Density:
1.299 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Dactolisib can be used for tumor cell proliferation studies.
Library Information
Targets:
PI3K/Akt/mTOR pathway
Receptors:
ATR; mTOR; mTOR (p70S6K); p110α; p110γ; p110δ
Pathways:
Autophagy; PI3K/Akt/mTOR signaling; DNA damage/DNA repair
Plate Number:
AOCL-6
Plate Location:
e7
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
1 mg/ml
Water Max Solubility:
<0.1 mg/mL (insoluble)
